ESC-Leitlinie 2022 onkologische Kardiologie

Michel, Lars; Totzeck, Matthias; Rassaf, Tienush

doi:10.1007/s00059-022-05149-z

Cited by 6 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For anthracycline chemotherapeutic drug-induced cardiotoxicity in humans, the guidelines in the U.S. and Europe differ in their criteria. The ESC2022 oncology cardiology guideline defines the lower limit of normal for the LVEF to be 50% ( Michel et al, 2022 ), whereas in the U.S. it is 53% ( Plana et al, 2014 ). Both guidelines emphasize a decrease in LVEF as an important marker of anthracycline cardiotoxicity.…”

Section: Animal Experiments Related To Anthracycline-induced Cardioto...mentioning

confidence: 99%

An update of the molecular mechanisms underlying anthracycline induced cardiotoxicity

Xie,

Sun,

Zhao

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Anthracycline drugs mainly include doxorubicin, epirubicin, pirarubicin, and aclamycin, which are widely used to treat a variety of malignant tumors, such as breast cancer, gastrointestinal tumors, lymphoma, etc. With the accumulation of anthracycline drugs in the body, they can induce serious heart damage, limiting their clinical application. The mechanism by which anthracycline drugs cause cardiotoxicity is not yet clear. This review provides an overview of the different types of cardiac damage induced by anthracycline-class drugs and delves into the molecular mechanisms behind these injuries. Cardiac damage primarily involves alterations in myocardial cell function and pathological cell death, encompassing mitochondrial dysfunction, topoisomerase inhibition, disruptions in iron ion metabolism, myofibril degradation, and oxidative stress. Mechanisms of uptake and transport in anthracycline-induced cardiotoxicity are emphasized, as well as the role and breakthroughs of iPSC in cardiotoxicity studies. Selected novel cardioprotective therapies and mechanisms are updated. Mechanisms and protective strategies associated with anthracycline cardiotoxicity in animal experiments are examined, and the definition of drug damage in humans and animal models is discussed. Understanding these molecular mechanisms is of paramount importance in mitigating anthracycline-induced cardiac toxicity and guiding the development of safer approaches in cancer treatment.

show abstract

Section: Animal Experiments Related To Anthracycline-induced Cardioto...mentioning

confidence: 99%

An update of the molecular mechanisms underlying anthracycline induced cardiotoxicity

Xie,

Sun,

Zhao

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…GLS is a relatively new parameter for HF patients, since it reflects the function of the heart’s longitudinal fibers. GLS emerged as a valuable parameter over the past few years because of its significant reliability and was included in the guidelines for what concerns the assessment of systolic function [ 60 , 75 ].…”

Section: Cardiac Remodelingmentioning

confidence: 99%

Sizing SGLT2 Inhibitors Up: From a Molecular to a Morpho-Functional Point of View

Prosperi,

D’Amato,

Severino

et al. 2023

IJMS

View full text Add to dashboard Cite

Sodium–glucose cotransporter 2 inhibitors (SGLT2i), or gliflozins, have recently been shown to reduce cardiovascular death and hospitalization in patients with heart failure, representing a revolutionary therapeutic tool. The purpose of this review is to explore their multifaceted mechanisms of actions, beyond their known glucose reduction power. The cardioprotective effects of gliflozins seem to be linked to the maintenance of cellular homeostasis and to an action on the main metabolic pathways. They improve the oxygen supply for cardiomyocytes with a considerable impact on both functional and morphological myocardial aspects. Moreover, multiple molecular actions of SGLT2i are being discovered, such as the reduction of both inflammation, oxidative stress and cellular apoptosis, all responsible for myocardial damage. Various studies showed controversial results concerning the role of SGLT2i in reverse cardiac remodeling and the lowering of natriuretic peptides, suggesting that their overall effect has yet to be fully understood. In addition to this, advanced imaging studies evaluating the effect on all four cardiac chambers are lacking. Further studies will be needed to better understand the real impact of their administration, their use in daily practice and how they can contribute to benefits in terms of reverse cardiac remodeling.

show abstract

Onkologische Kardiologie

Michel,

Rassaf

2024

DGIM Innere Medizin

Self Cite

View full text Add to dashboard Cite

Onkologische Kardiologie Konsensuspapier der Deutschen Gesellschaft für Kardiologie -Herz-und Kreislaufforschung, der Deutschen Gesellschaft für Pädiatrische Kardiologie und Angeborene Herzfehler und der Deutschen Gesellschaft für Hämatologie und Medizinische Onkologie Aus Gründen der besseren Lesbarkeit und Verständlichkeit der Texte wird in Springer-Publikationen in der Regel das generische Maskulinum als geschlechtsneutrale Form verwendet. Diese Form impliziert immer alle Geschlechter. Dieses Konsensuspapier wird simultan in deutscher Sprache in Der Kardiologe

show abstract

ESC-Leitlinie 2022 onkologische Kardiologie

Cited by 6 publications

References 17 publications

An update of the molecular mechanisms underlying anthracycline induced cardiotoxicity

An update of the molecular mechanisms underlying anthracycline induced cardiotoxicity

Sizing SGLT2 Inhibitors Up: From a Molecular to a Morpho-Functional Point of View

Onkologische Kardiologie

Contact Info

Product

Resources

About